Duke University and Affymetrix Initiate Five-Year Translational Research Collaboration
News Jan 10, 2006
Affymetrix Inc. has announced that it has entered into five-year collaboration with Duke University to analyze genomic information across large patient samples.
Under terms of the agreement, Duke researchers will use Affymetrix GeneChip® microarray technology to develop applications for translational research projects. The initial projects will focus on cancer and cardiovascular disease.
Duke researchers will use Affymetrix's GeneChip HT System and arrays to perform large-scale clinical studies.
The Affymetrix technology will enable them to discover RNA and DNA patterns that can better classify, manage and treat complex diseases.
As part of the agreement, Affymetrix will fund creative research and clinical projects that could lead to new genomic applications on the GeneChip platform, as well as diagnostics and screening tests.
"This is an exciting time when genomics offers the promise of a deeper understanding of biology while at the same time improving the practice of medicine," said Joseph Nevins, Ph.D., director of the IGSP Center for Applied Genomics & Technology at Duke University.
"By combining our research expertise with Affymetrix's high-throughput microarray technology, we have the opportunity to build on our prior work and develop gene expression profiles that characterize oncogenic pathways and define tumor phenotypes, which are important in determining clinical outcomes."
"At the same time, this can translate into improved clinical care and provide an important resource to enhance the use of microarray technology for all Duke investigators."
"Affymetrix is excited to be working with a leading research organization such as Duke University to help bring more effective personalized tests and therapies to market faster," said Gregg Fergus, senior vice president, Global Sales Operations at Affymetrix.
"Together, we hope to accelerate clinical research, improve patient care and open the door to new genomic applications."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE